- Home
- SEE vs KRYS Comparison
SEE vs KRYS Comparison
Compare SEE & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEE
- KRYS
- Stock Information
- Founded
- SEE 1960
- KRYS 2015
- Country
- SEE United States
- KRYS United States
- Employees
- SEE N/A
- KRYS N/A
- Industry
- SEE Major Chemicals
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEE Industrials
- KRYS Health Care
- Exchange
- SEE Nasdaq
- KRYS Nasdaq
- Market Cap
- SEE 5.1B
- KRYS 4.7B
- IPO Year
- SEE N/A
- KRYS 2017
- Fundamental
- Price
- SEE $34.06
- KRYS $185.34
- Analyst Decision
- SEE Strong Buy
- KRYS Strong Buy
- Analyst Count
- SEE 10
- KRYS 9
- Target Price
- SEE $41.60
- KRYS $210.22
- AVG Volume (30 Days)
- SEE 1.3M
- KRYS 268.8K
- Earning Date
- SEE 11-04-2025
- KRYS 11-03-2025
- Dividend Yield
- SEE 2.33%
- KRYS N/A
- EPS Growth
- SEE N/A
- KRYS 36.22
- EPS
- SEE 1.98
- KRYS 4.91
- Revenue
- SEE $5,325,400,000.00
- KRYS $359,205,000.00
- Revenue This Year
- SEE N/A
- KRYS $34.33
- Revenue Next Year
- SEE $2.00
- KRYS $48.12
- P/E Ratio
- SEE $17.41
- KRYS $38.66
- Revenue Growth
- SEE N/A
- KRYS 116.08
- 52 Week Low
- SEE $22.78
- KRYS $122.80
- 52 Week High
- SEE $38.85
- KRYS $207.84
- Technical
- Relative Strength Index (RSI)
- SEE 47.12
- KRYS 55.27
- Support Level
- SEE $34.29
- KRYS $185.05
- Resistance Level
- SEE $35.60
- KRYS $191.88
- Average True Range (ATR)
- SEE 0.79
- KRYS 6.66
- MACD
- SEE -0.14
- KRYS -1.44
- Stochastic Oscillator
- SEE 38.15
- KRYS 34.97
About SEE Sealed Air Corporation
Sealed Air is organized via two reporting segments. Food includes food packaging products like Cryovac, Darfresh, and OptiDure aimed primarily at meats. Protective includes Sealed Air's Bubble Wrap, Instapak, Jiffy mailers, and shrink film packaging systems that cater to industrial and e-commerce applications.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.